Lindsey Shapiro, PhD, science writer —

The U.S. Food and Drug Administration (FDA) has approved Boruzu, a ready-to-use injectable formulation of bortezomib, for treating adults with multiple myeloma and mantle cell lymphoma. While a bortezomib formulation sold as Velcade has been used for years for these forms of blood cancer, Boruzu is expected to…

Supporters are gearing up to learn, educate, and fundraise in observance of Blood Cancer Awareness Month, which is held each September to increase awareness of all types of blood cancer, including myeloma, lymphoma, and leukemia. The International Myeloma Foundation (IMF) will revive its #kNOwMyeloma educational campaign, which…

The U.S. Food and Drug Administration (FDA) has approved a new quadruple regimen including Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a first-line approach for adults with newly diagnosed multiple myeloma and eligible for a stem cell transplant. Johnson & Johnson’s Darzalex Faspro now can be used in…

Researchers in Germany have identified proteins that could help identify multiple myeloma patients who at high risk for an aggressive disease course and worse prognosis. Across a series of experiments, the scientists uncovered protein-level molecular changes that appeared specific to myeloma and correlated with disease progression patterns and myeloma…

GSK‘s Blenrep (belantamab mafodotin) cut the risk of cancer progression nearly in half compared with bortezomib when used in combination with other therapies to treat multiple myeloma patients who’d had at least one previous disease relapse. The benefits of Blenrep, used in combination with Pomalyst (pomalidomide) and…

NXC-201, an investigational CAR T-cell therapy, has been designated an orphan drug in the European Union (EU) as a potential treatment of multiple myeloma. This status aims to speed the therapy’s clinical development by providing incentives that include reduced regulatory fees. It also gives access to the EU centralized…

Combining the cancer therapy Venclexta (venetoclax) with a molecule called 5-azacytidine (5-aza) increased the former’s ability to kill lab-grown cancer cells derived from a range of different multiple myeloma patients regardless of their disease stage, a study showed. While Venclexta is known to benefit only myeloma patients with…

The European Commission has approved Bristol Myers Squibb (BMS)’s request to expand the use of the CAR T-cell therapy Abecma (idecabtagene vicleucel) as an earlier line of therapy for adults with multiple myeloma that’s difficult to treat. The therapy was already approved in the European Union (EU) for…

The U.S. Food and Drug Administration (FDA) has cleared an every-other-week dosing regimen of Tecvayli (teclistamab) for relapsed or refractory (hard-to-treat) multiple myeloma (RRMM) patients who have responded well to the therapy’s standard weekly dosing. Tecvayli was initially approved in 2022 for adults with RRMM who had…

The European Medicines Agency has agreed to review Regeneron Pharmaceuticals’ application seeking approval of its investigational therapy linvoseltamab for adults in Europe with relapsed or refractory multiple myeloma (RRMM), according to a company press release. A similar application was submitted to the U.S. Food and Drug Administration…